View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar II. Belgyógyászati Klinika Budapest Szentkirályi u. 36. 1088
  • 2 Magyar Tudományos Akadémia – Semmelweis Egyetem Molekuláris Medicina Kutató Csoport Budapest
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

A májtranszplantációk fő indikációja a hepatitis C-fertőzés következtében kialakult végstádiumú C-cirrhosis hepatitis. A transzplantáció után a HCV-fertőzés visszatérése általános, a rekurráló C-hepatitis progresszív betegség, kezelés nélkül az immunszuppresszió mellett öt éven belül a betegek 20%-ában cirrhosist okoz. A visszatérő HCV-fertőzés kezelése a transzplantált betegek túlélésének legfontosabb meghatározó tényezője. A szerzők az irodalmi adatok és saját tapasztalatuk alapján áttekintik a kiújuló HCV-fertőzés kimenetelét befolyásoló tényezőket. Részletezik az immunszuppresszív kezelés hatását, a megfelelő immunszuppresszív gyógyszer kiválasztásának fontosságát. Áttekintik a visszatérő C-hepatitis diagnózisának fő szempontjait, hangsúlyozzák a protokoll szerint végzett májbiopsziák meghatározó szerepét a diagnózisban, a patológus, a hepatológus és a sebész szoros együttműködését. Ismertetik a várólistán lévő betegek kezelésével szerzett tapasztalatokat, a kiújult krónikus hepatitis korai preemptív kezelési eredményeit és a már szövettani elváltozásban megnyilvánuló krónikus C-hepatitis kezelési lehetőségeit és eredményeit. A transzplantáción átesett betegek krónikus C-hepatitisének jelenleg elfogadott gyógyszere a pegilált interferon és ribavirin kombinációja. Ezzel a terápiával a betegek 20–50%-ában tartós vírusmentesség érhető el. A vírusmentes betegekben egyértelműen csökken a májszövetben a gyulladásos aktivitás, javul a szövettani aktivitási index. A kezelés fibrózisgátló hatására is vannak adatok, ezek további megerősítése azonban multicentrikus vizsgálatokat igényel. A legtöbb tanulmány nem igazolja a korai, szövettani eltérés nélküli antivirális kezelés előnyét. Ebben a betegcsoportban a kezelés gyakori mellékhatása az anémia és a neutropenia, ezért ajánlott az erythropoetin és a granulocyta-stimuláló faktor adása. A rekurráló C-hepatitisben szenvedő betegek optimális kezelése, a pegilált interferon és ribavirin dózisának meghatározása, a terápia időtartama, a mellékhatások csökkentése, a nagyobb arányú gyógyulás elérése további vizsgálatokat, klinikai tanulmányokat tesz szükségessé.

  • Belle, S. H., Beringer, K. C., Detre, K. M.: Recent findings concerning liver transplantation in the United States. Clin. Transpl., 1996, 10 , 15–29.

    Detre K. M. , 'Recent findings concerning liver transplantation in the United States ' (1996 ) 10 Clin. Transpl. : 15 -29.

    • Search Google Scholar
  • Nemes B., Sárváry E., Gerlei Zs. és mtsai: Hepatitis C-vírus kiújulása májátültetés után. Orv. Hetil., 2007, 148 , 1971–1979.

    Gerlei Zs. , 'Hepatitis C-vírus kiújulása májátültetés után ' (2007 ) 148 Orv. Hetil. : 1971 -1979.

    • Search Google Scholar
  • Forman, L. M., Lewis, J. D., Berlin, J. A. és mtsai: The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology, 2002, 122 , 889–896.

    Berlin J. A. , 'The association between hepatitis C infection and survival after orthotopic liver transplantation ' (2002 ) 122 Gastroenterology : 889 -896.

    • Search Google Scholar
  • Garcia-Retortillo, M., Forns, X., Feliu, A. és mtsai: Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology, 2002, 35 , 680–687.

    Feliu A. , 'Hepatitis C virus kinetics during and immediately after liver transplantation ' (2002 ) 35 Hepatology : 680 -687.

    • Search Google Scholar
  • Berenguer, M., Lopez-Labrador, F. X., Wright, T. L.: Hepatitis C and liver transplantation. J. Hepatol, 2001, 35 , 666–678.

    Wright T. L. , 'Hepatitis C and liver transplantation ' (2001 ) 35 J. Hepatol : 666 -678.

  • Fukumoto, T., Berg, T., Ku, Y. és mtsai: Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions. Hepatology, 1996, 24 , 1351–1354.

    Ku Y. , 'Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions ' (1996 ) 24 Hepatology : 1351 -1354.

    • Search Google Scholar
  • Gane, E. J., Naoumov, N. V., Qian, K. P. és mtsai: A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology, 1996, 110 , 167–177.

    Qian K. P. , 'A longitudinal analysis of hepatitis C virus replication following liver transplantation ' (1996 ) 110 Gastroenterology : 167 -177.

    • Search Google Scholar
  • Sanchez-Fueyo, A., Restrepo, J. C., Quinto, L. és mtsai: Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation, 2002, 15, 73 , 56–63.

    Quinto L. , 'Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft ' (2002 ) 15 Transplantation : 56 -63.

    • Search Google Scholar
  • Berenguer, M., Rayon, J. M., Priet, M. és mtsai: Are posttransplantation protocol liver biopsies useful in the long term? Liver Transpl., 2001, 7 , 790–796.

    Priet M. , 'Are posttransplantation protocol liver biopsies useful in the long term? ' (2001 ) 7 Liver Transpl. : 790 -796.

    • Search Google Scholar
  • Bahra, M., Neumann, U. P., Jacob, D. és mtsai: Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss. Transpl. Proc., 2005, 37 , 1700–1702.

    Jacob D. , 'Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss ' (2005 ) 37 Transpl. Proc. : 1700 -1702.

    • Search Google Scholar
  • Berenguer, M.: Natural history of recurrent hepatitis C. Liver Transplant., 2002, 8 , 14–18.

    Berenguer M. , 'Natural history of recurrent hepatitis C ' (2002 ) 8 Liver Transplant. : 14 -18.

    • Search Google Scholar
  • Neumann, U. P., Berg, T., Bahra, M. és mtsai: Fibrosis progression after liver transplantation in patients with reccurent hepatitis C. J. Hepatol., 2004, 41 , 830–836.

    Bahra M. , 'Fibrosis progression after liver transplantation in patients with reccurent hepatitis C ' (2004 ) 41 J. Hepatol. : 830 -836.

    • Search Google Scholar
  • Nemes B., Sárváry E., Kóbori L. és mtsai: Serum hepatitis C vírus – ribonucleotide acid monitoring after liver transplantation. The Hungarian experience. Dig. Liver Dis., 2005, 37 , 68–69.

    Kóbori L. , 'Serum hepatitis C vírus – ribonucleotide acid monitoring after liver transplantation. The Hungarian experience ' (2005 ) 37 Dig. Liver Dis. : 68 -69.

    • Search Google Scholar
  • Testa, G., Crippin, J. S., Netto, G. J. és mtsai: Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transpl., 2000, 6 , 553–561.

    Netto G. J. , 'Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients ' (2000 ) 6 Liver Transpl. : 553 -561.

    • Search Google Scholar
  • Zhou, S., Terrault, N. A., Ferrell, L. és mtsai: Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology, 1996, 24 , 1041–1046.

    Ferrell L. , 'Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia ' (1996 ) 24 Hepatology : 1041 -1046.

    • Search Google Scholar
  • Martin, P., Busuttil, R. W., Goldstein, R. M. és mtsai: Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl., 2004, 10 , 1258–1262.

    Goldstein R. M. , 'Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial ' (2004 ) 10 Liver Transpl. : 1258 -1262.

    • Search Google Scholar
  • Firpi, R. J., Zhu, H., Morelli, G. és mtsai: Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl., 2006, 12 , 51–57.

    Morelli G. , 'Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation ' (2006 ) 12 Liver Transpl. : 51 -57.

    • Search Google Scholar
  • Selzner, N., Girgrah, N., Al Adawi, I. és mtsai: Genotype and choice of calcineurin inhibitor influence response to antiviral therapy in liver transplant recipients treated for recurrent HCV. Hepatology, 2006, 44 , 785.

    Adawi I. , 'Genotype and choice of calcineurin inhibitor influence response to antiviral therapy in liver transplant recipients treated for recurrent HCV ' (2006 ) 44 Hepatology : 785 -.

    • Search Google Scholar
  • Berenguer, M., Palau, A., Fernandez, A. és mtsai: Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl., 2006, 12 , 1067–1076.

    Fernandez A. , 'Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C ' (2006 ) 12 Liver Transpl. : 1067 -1076.

    • Search Google Scholar
  • Berenguer, M.: What determines the natural history of recurrent hepatitis C after liver transplantation? J. Hepatol., 2005, 42 , 448–456.

    Berenguer M. , 'What determines the natural history of recurrent hepatitis C after liver transplantation? ' (2005 ) 42 J. Hepatol. : 448 -456.

    • Search Google Scholar
  • Llado, L., Xiol, X., Figueras, J. és mtsai: Immunsuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study. J. Hepatol., 2006, 44 , 710–716.

    Figueras J. , 'Immunsuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study ' (2006 ) 44 J. Hepatol. : 710 -716.

    • Search Google Scholar
  • Margarit, C., Bilbao, I., Castells, L. és mtsai: A prospective randomized trial comparing tacrolimus and steroid with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C. Transplant. Int., 2005, 18 , 1336–1345.

    Castells L. , 'A prospective randomized trial comparing tacrolimus and steroid with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C ' (2005 ) 18 Transplant. Int. : 1336 -1345.

    • Search Google Scholar
  • Neuhaus, P., Clavien, P-A., Kittur, D. és mtsai: Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl., 2002, 8 , 132–142.

    Kittur D. , 'Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial ' (2002 ) 8 Liver Transpl. : 132 -142.

    • Search Google Scholar
  • Jain, A., Kashyap, R., Demetris, A. J. és mtsai: A prospective randomized trial of mycophenolate mofetiel in liver transplant recipients with hepatitis C. Liver Transpl., 2002, 8 , 40–46.

    Demetris A. J. , 'A prospective randomized trial of mycophenolate mofetiel in liver transplant recipients with hepatitis C ' (2002 ) 8 Liver Transpl. : 40 -46.

    • Search Google Scholar
  • Wiesner, R. H., Shorr, J. S., Steffen, B. J. és mtsai: Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl., 2005, 11 , 750–759.

    Steffen B. J. , 'Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C ' (2005 ) 11 Liver Transpl. : 750 -759.

    • Search Google Scholar
  • Russo, M. W., Galanko, J., Beavers, K. és mtsai: Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl., 2004, 10 , 340–346.

    Beavers K. , 'Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States ' (2004 ) 10 Liver Transpl. : 340 -346.

    • Search Google Scholar
  • Neff, G. W., Shire, N., Ruiz, P. és mtsai: The importance of clinical parameters when differentiating cholestatic hepatitis C virus from allograft rejection. Transpl. Proc., 2005, 37 , 4397–4402.

    Ruiz P. , 'The importance of clinical parameters when differentiating cholestatic hepatitis C virus from allograft rejection ' (2005 ) 37 Transpl. Proc. : 4397 -4402.

    • Search Google Scholar
  • Patonai A., Nemes B., Görög D. és mtsai: A hazai májtranszplantációk értékelése patológiai szempontból. Orv. Hetil., 2001, 142 , 435–441.

    Görög D. , 'A hazai májtranszplantációk értékelése patológiai szempontból ' (2001 ) 142 Orv. Hetil. : 435 -441.

    • Search Google Scholar
  • Baiocchi, L., Tisone, G., Palmieri, G. és mtsai: Hepatic steatosis: a specific sign of hepatitis C reinfection after liver transplantation. Liver Transpl., 1998, 4 , 441–447.

    Palmieri G. , 'Hepatic steatosis: a specific sign of hepatitis C reinfection after liver transplantation ' (1998 ) 4 Liver Transpl. : 441 -447.

    • Search Google Scholar
  • Regev, A., Molina, E., Moura, R. és mtsai: Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation. Liver Transpl., 2004, 10 , 1233–1239.

    Moura R. , 'Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation ' (2004 ) 10 Liver Transpl. : 1233 -1239.

    • Search Google Scholar
  • Wiesner, R. H., Sorrell, M., Villamil, F. és mtsai: Report of the first international Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl., 2003, 9 , 1–9.

    Villamil F. , 'Report of the first international Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C ' (2003 ) 9 Liver Transpl. : 1 -9.

    • Search Google Scholar
  • Stravitz, R. T., Shiffman, M. L., Sanyal, A. J. és mtsai: Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl., 2004, 10 , 850–858.

    Sanyal A. J. , 'Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation ' (2004 ) 10 Liver Transpl. : 850 -858.

    • Search Google Scholar
  • Davis, G. L., Nelson, D. R., Terrault, N. és mtsa: A randomized, openlabel study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl., 2005, 11 , 941–949.

    Terrault N. , 'A randomized, openlabel study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients ' (2005 ) 11 Liver Transpl. : 941 -949.

    • Search Google Scholar
  • Eren, R., Landstein, D., Terkieltaub, D. és mtsai: Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J. Virol., 2006, 80 , 2654–2664.

    Terkieltaub D. , 'Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients ' (2006 ) 80 J. Virol. : 2654 -2664.

    • Search Google Scholar
  • Everson, G. T., Trotter, J., Forman, L. és mtsai: Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology, 2005, 42 , 255–262.

    Forman L. , 'Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy ' (2005 ) 42 Hepatology : 255 -262.

    • Search Google Scholar
  • Forns, X., Garcia-Retortillo, M., Serrano, T. és mtsai: Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J. Hepatol., 2003, 39 , 389–396.

    Serrano T. , 'Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation ' (2003 ) 39 J. Hepatol. : 389 -396.

    • Search Google Scholar
  • Martinez-Bauer, E., Carrion, J. A., Ramirez, S. és mtsai: Antiviral therapy of patients with decompensated cirrhosis to prevent hepatitis C recurrence after liver transplantation. J. Hepatol., 2006, 44, (Suppl. 2) , 64.

    Ramirez S. , 'Antiviral therapy of patients with decompensated cirrhosis to prevent hepatitis C recurrence after liver transplantation ' (2006 ) 44 J. Hepatol. : 64 -.

    • Search Google Scholar
  • Zileri Dal Verme, L., Ilyas, J. A., Merra, G. és mtsai: HCV treatment in patients with end stage liver disease awaiting liver transplantation. J. Hepatol., 2006, 44 (Suppl. 2) , 232.

    Merra G. , 'HCV treatment in patients with end stage liver disease awaiting liver transplantation ' (2006 ) 44 J. Hepatol. : 232 -.

    • Search Google Scholar
  • Sheiner, P. A., Boros P., Klion, F. M. és mtsai: The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology, 1998, 28 , 831–838.

    Klion F. M. , 'The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation ' (1998 ) 28 Hepatology : 831 -838.

    • Search Google Scholar
  • Mazzaferro, V., Tagger, A., Schiavo, M. és mtsai: Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transpl. Proc., 2001, 33 , 1355–13357.

    Schiavo M. , 'Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment ' (2001 ) 33 Transpl. Proc. : 1355 -13357.

    • Search Google Scholar
  • Shergill, A. K., Khalili, M., Straley, S. és mtsai: Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C infected patients undergoing liver transplantation. Am. J. Transpl., 2005, 5 , 118–124.

    Straley S. , 'Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C infected patients undergoing liver transplantation ' (2005 ) 5 Am. J. Transpl. : 118 -124.

    • Search Google Scholar
  • Chalasani, N., Manzarbeitia, C., Ferenci P. és mtsai: Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology, 2005, 41 , 289–298.

    Ferenci P. , 'Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials ' (2005 ) 41 Hepatology : 289 -298.

    • Search Google Scholar
  • Kuo, A., Lan, B., Feng, S. és mtsai: Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus (HCV) infection [abstract]. Hepatology, 2006, 44 (Suppl. 1) , A3.

    Feng S. , 'Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus (HCV) infection [abstract] ' (2006 ) 44 Hepatology : A3 -.

    • Search Google Scholar
  • Abdelmalek, M. F., Firpi, R. J., Soldevila-Pico, C. és mtsai: Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl., 2004, 10 , 199–207.

    Soldevila-Pico C. , 'Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C ' (2004 ) 10 Liver Transpl. : 199 -207.

    • Search Google Scholar
  • Samuel, D., Bizollon, T., Feray, C. és mtsai: Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology, 2003, 124 , 642–650.

    Feray C. , 'Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study ' (2003 ) 124 Gastroenterology : 642 -650.

    • Search Google Scholar
  • Lengyel G., Kóbori L., Fehérvári I.: Kombinált interferon-alfa-2b és ribavirin terápia májtranszplantációt követő krónikus C-hepatitisben. Orv. Hetil., 2003, 144 , 2367–2370.

    Fehérvári I. , 'Kombinált interferon-alfa-2b és ribavirin terápia májtranszplantációt követő krónikus C-hepatitisben ' (2003 ) 144 Orv. Hetil. : 2367 -2370.

    • Search Google Scholar
  • Dumortier, J., Scoazec, J. Y., Chevallier, P. és mtsai: Treatment of reccurent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J. Hepatol., 2004, 40 , 669–674.

    Chevallier P. , 'Treatment of reccurent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination ' (2004 ) 40 J. Hepatol. : 669 -674.

    • Search Google Scholar
  • Moreno Planas, J. M., Rubio Gonzalez, E., Boullosa Grana, E. és mtsai: Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation. Transpl. Proc., 2005, 37 , 2207–2208.

    Boullosa Grana E. , 'Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation ' (2005 ) 37 Transpl. Proc. : 2207 -2208.

    • Search Google Scholar
  • Aesatie, M., Chalasani, N. és Kwo, P. Y.: Management of Hepatitis C Infection after Liver Transplantation. Drugs, 2007, 67 , 871–885.

    Kwo P. Y. , 'Management of Hepatitis C Infection after Liver Transplantation ' (2007 ) 67 Drugs : 871 -885.

    • Search Google Scholar
  • Kuo, A., Terrault, N. A.: Antiviral therapy in liver transplant recipients: Is SVR the only endpoint that matters? J. Hepatol., 2007, 46 , 359–361.

    Terrault N. A. , 'Antiviral therapy in liver transplant recipients: Is SVR the only endpoint that matters? ' (2007 ) 46 J. Hepatol. : 359 -361.

    • Search Google Scholar
  • Dumortier, J., Ducos, E., Scoazec, J. Y. és mtsai: Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation. J. Viral Hepatitis, 2006, 13 , 538–543.

    Scoazec J. Y. , 'Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation ' (2006 ) 13 J. Viral Hepatitis : 538 -543.

    • Search Google Scholar
  • Paterson, D. L., Gayowski, T., Wannstedt, C. F. és mtsai: Quality of life in long-term survivors after liver transplantation: impact of recurrent viral hepatitis C virus hepatitis. Clin. Transpl., 2000, 14 , 48–54.

    Wannstedt C. F. , 'Quality of life in long-term survivors after liver transplantation: impact of recurrent viral hepatitis C virus hepatitis ' (2000 ) 14 Clin. Transpl. : 48 -54.

    • Search Google Scholar